Ardelyx, Inc. Files 8-K
Ticker: ARDX · Form: 8-K · Filed: Jul 2, 2024 · CIK: 1437402
| Field | Detail |
|---|---|
| Company | Ardelyx, Inc. (ARDX) |
| Form Type | 8-K |
| Filed Date | Jul 2, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, regulatory
Related Tickers: ARDX
TL;DR
Ardelyx filed a routine 8-K, no major news.
AI Summary
Ardelyx, Inc. filed an 8-K on July 2, 2024, to report other events and financial statements. The company, formerly known as Nteryx Inc., is incorporated in Delaware and headquartered in Waltham, Massachusetts. The filing does not disclose specific financial figures or material events beyond its routine reporting nature.
Why It Matters
This 8-K filing indicates Ardelyx, Inc. is fulfilling its regulatory reporting obligations with the SEC, which is standard for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for 'Other Events' and 'Financial Statements and Exhibits' without disclosing specific material events or financial data.
Key Players & Entities
- ARDELYX, INC. (company) — Registrant
- NTERYX INC (company) — Former Company Name
- July 2, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Waltham, Massachusetts (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Ardelyx, Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of July 2, 2024.
What was Ardelyx, Inc.'s former company name?
Ardelyx, Inc.'s former company name was NTERYX INC.
In which state is Ardelyx, Inc. incorporated?
Ardelyx, Inc. is incorporated in Delaware.
Where are Ardelyx, Inc.'s principal executive offices located?
Ardelyx, Inc.'s principal executive offices are located at 400 Fifth Avenue, Suite 210, Waltham, Massachusetts 02451.
Does this filing disclose any specific material events or financial results?
No, this filing is a standard 8-K reporting 'Other Events' and 'Financial Statements and Exhibits' and does not disclose specific material events or financial results.
Filing Stats: 434 words · 2 min read · ~1 pages · Grade level 12 · Accepted 2024-07-02 07:04:27
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 ARDX The Nasdaq Global Market Indicat
Filing Documents
- ardx-20240702.htm (8-K) — 25KB
- ardx-20240702_g1.jpg (GRAPHIC) — 3KB
- 0001628280-24-030708.txt ( ) — 156KB
- ardx-20240702.xsd (EX-101.SCH) — 2KB
- ardx-20240702_lab.xml (EX-101.LAB) — 22KB
- ardx-20240702_pre.xml (EX-101.PRE) — 13KB
- ardx-20240702_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On July 2, 2024, Ardelyx, Inc. (the Company) announced that, in an effort to preserve patient access to its phosphate absorption inhibitor XPHOZAH (tenapanor), the Company has chosen not to apply to include XPHOZAH in the Centers for Medicare & Medicaid Services (CMS) End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) Transitional Drug Add-on Payment Adjustment (TDAPA).
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 2, 2024 ARDELYX, INC. By: /s/ Justin Renz Justin Renz Chief Financial and Operations Officer